Novartis AG $NVS Stock Bought by First Command Advisory Services Inc.

First Command Advisory Services Inc. raised its stake in shares of Novartis AG (NYSE:NVS) by 206.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,582 shares of the company’s stock after purchasing an additional 8,474 shares during the period. First Command Advisory Services Inc.’s holdings in Novartis were worth $1,794,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of NVS. WCM Investment Management LLC bought a new stake in Novartis in the first quarter worth $220,004,000. Bank of America Corp DE raised its stake in shares of Novartis by 9.1% in the first quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock valued at $758,067,000 after acquiring an additional 413,778 shares during the period. Miller Howard Investments Inc. NY bought a new stake in shares of Novartis in the 3rd quarter worth about $32,737,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Novartis by 40.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 195,986 shares of the company’s stock worth $30,715,000 after acquiring an additional 56,424 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in shares of Novartis by 9.6% during the 1st quarter. Sei Investments Co. now owns 619,274 shares of the company’s stock worth $94,594,000 after purchasing an additional 54,262 shares during the period. 13.12% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Weiss Ratings downgraded shares of Novartis from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, November 4th. The Goldman Sachs Group reissued a “sell” rating on shares of Novartis in a research note on Monday, September 21st. Sanford C. Bernstein restated a “neutral” rating on shares of Novartis in a research report on Wednesday, July 22nd. Bank of America reaffirmed a “buy” rating on shares of Novartis in a research note on Tuesday, September 8th. Finally, Deutsche Bank cut Novartis from a “hold” rating to a “sell” rating in a research note on Friday, October 30th. Six analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $152.25.

Trending Headlines about Novartis

Investors following NVS have been watching these headlines:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $9.06 from $8.83 and its FY2027 estimate to $9.91 from $9.75. It also lifted several quarterly forecasts, including Q3 2027. Novartis coverage
• Positive Sentiment: Novartis reported two-year ianalumab study data showing continued benefits in Sjögren’s disease. The update may support the drug’s development potential, though it does not by itself establish commercial success. Novartis presents long-term ianalumab data Ianalumab two-year study results
• Negative Sentiment: The estimate changes were not uniformly positive: Zacks lowered its Q4 2026, Q1 2027, Q1 2028 and Q2 2028 EPS forecasts. These trims could temper the positive signal from higher annual estimates.

Novartis Trading Down 1.7%

Shares of NVS opened at $160.41 on Thursday. Novartis AG has a 1-year low of $123.24 and a 1-year high of $170.46. The company has a 50-day moving average of $149.23 and a 200 day moving average of $152.50. The firm has a market capitalization of $306.08 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 3.00 and a beta of 0.40. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.88 and a quick ratio of 0.70.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, October 27th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.25 by $0.21. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.53 billion. Novartis had a net margin of 18.11% and a return on equity of 41.04%. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.25 EPS. On average, research analysts expect that Novartis AG will post 9.08 EPS for the current year.

Novartis Company Profile

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.